SpeedWeed

SEPTEMBER 1, 2021

They can download the forms and instructions for free on our website and follow the instructions for the remainder of the process,” said Paula Collins, administrator of the Law Library Resource Center. grams can be a cannabis concentrate or extract—are eligible to have their records expunged. .

Advocacy 58

Advocacy Programs Cultivation Cannabis 58

Cannabis Law Report

OCTOBER 16, 2019

The sign may be downloaded from the Liquor and Cannabis Board website here. This disclosure form can be found here. Please follow the instructions within the document and submit to mjdisclosureform@lcb.wa.gov. Note : please note that this sign is different than the sign provided earlier.

Vaping 45

Vaping Concentrates Extraction Terpenes 45

Cannabis Law Report

SEPTEMBER 15, 2021

As a result, concentrated amounts of delta-8 THC are typically manufactured from hemp-derived cannabidiol (CBD). . Some concerns include variability in product formulations and product labeling, other cannabinoid and terpene content, and variable delta-8 THC concentrations. synthetic conversion).

THC 105

THC Pets Events Hemp 105

Project CBD

FEBRUARY 28, 2023

According to the FDA, “hemp” is defined as Cannabis sativa with a tetrahydrocannabinol (THC) concentration of 0.3% 1 SPINS’ CBD category typically includes sales of products that contain hemp-based CBD extracts, including CBD oils, gummies, and capsules. Available at: www.fda.gov/media/131878/download. Accessed October 17, 2022.

CBD 144

CBD Seed-To-Sale Food Access 144

Cannabis Law Report

DECEMBER 8, 2019

This is particularly important in the United States with respect to the FDA, which has bemoaned a lack of data it can use to create policy and regulations of cannabis products, and in Europe with respect to the Food Safety Division of the European Commission’s application of the Novel Foods designation to cannabidiol (CBD). September 2017.

Medicine 59

Medicine Research and Development Food Cannabinoids 59

Cannabis Law Report

NOVEMBER 24, 2021

However, the nature of the government regulations and the subsequent complexity of prescribing, as well as doctors’ safety uncertainties and the stigma of the plant, remain contributing barriers to patient access. Framings that more often carried a negative tone were related to poor evidence and safety issues.

Research and Development 52

Research and Development Medicine Access Media 52

Meadow

DECEMBER 24, 2017

And then you see the consumption version of that, where folks would be sold a small amount of cannabis or concentrate that they could use on site. We’ve had this debate here in San Francisco about what does over-concentration look like. And in a very concentrated city I think that looks a lot different.

Packaging 40

Packaging Retail Edibles Wellness and Beauty 40